FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

wasnington,	D.C. 20549	

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL

OMB Number: 3235-0287

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Takimoto Chris H						2. Issuer Name and Ticker or Trading Symbol  IGM Biosciences, Inc. [ IGMS ]									all app Direc Office	er (give title	ng Per	10% Ov	wner
(Last) (First) (Middle) C/O IGM BIOSCIENCES, INC. 325 E. MIDDLEFIELD ROAD					3. Date of Earliest Transaction (Month/Day/Year) 12/16/2022									below) below)  Chief Medical Officer					
(Street) MOUNT VIEW	'AIN CA	A 94043			4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									dividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City)	(Sta	ate) (Ž	Zip)																
		Table	I - I	Non-Deriva	tive	Secui	rities	Ac	quir	ed, D	isposed	of, or	Benefic	cially	Own	ed			
1. Title of Security (Instr. 3)  2. Transactio Date (Month/Day/Y				ear) E	2A. Deeme Execution if any (Month/Day		n Date,		ection Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 an			d 5) Securi		icially d Following	Form (D) o	n: Direct r ect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							С		Code	v	Amount	(A) or (D)	Price		Transa	saction(s) r. 3 and 4)		1. 4)	(111501. 4)
Common Stock 12			12/16/202	2		5		S <sup>(1)</sup>		3,492	D	\$18.77	746 <sup>(2)</sup>	3.	32,495		D		
Common Stock 12/16/2			12/16/202	2			S			1,938	D	\$19.35	595 <sup>(3)</sup>	30,557			D		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Descrity or Exercise (Month/Day/Year) if any			cution Date,	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Exp (Mo	oiration	ercisable and Date y/Year)	and 7. Title and Amount of Securities Underlying Derivative Security (Ins 3 and 4)		Der Sec (Ins	rice of ivative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	y   0	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Dat Exe	e ercisab	Expiration Date	on Title	Amount or Number of Shares	r					

## Explanation of Responses:

- 1. These shares were sold to cover tax withholding obligations in connection with the vesting of restricted stock units.
- 2. This transaction was executed in multiple trades at prices ranging from \$18.29 to \$19.289. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- 3. This transaction was executed in multiple trades at prices ranging from \$19.30 to \$19.47. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

## Remarks:

/s/ Misbah Tahir, by power of attorney

12/20/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.